FLHLF News and Press, Filament Health From 03/15/22

Filament Health (FLHLF) CEO Ben Lightburn provides a preview of their upcoming presentation at NobleCon18 NobleCon18 - Noble Capital Markets 18th Annual Small and Microcap Investor Conference - April 19-21, 2022 - Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts...

Filament Health (OTCQB: FLHLF) is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon ...

Filament Health to Participate in the 34th Annual Roth Conference Canada NewsWire VANCOUVER, BC , March 8, 2022 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development...

Filament Health and ATMA Journey Centers Announce Licensing Agreement Canada NewsWire ATMA will use Filament's proprietary botanical drug candidate for clinical trials VANCOUVER, BC , Feb. 23, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO...

FILAMENT HEALTH REFILES Q2 AND Q3 INTERIM FINANCIAL STATEMENTS AND MD&A FILAMENT HEALTH REFILES Q2 AND Q3 INTERIM FINANCIAL STATEMENTS AND MD&A Canada NewsWire VANCOUVER, BC , Feb. 22, 2022 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) ...

FILAMENT HEALTH AND CYBIN THERAPEUTICS ANNOUNCE APPROVAL FOR PHASE II CLINICAL TRIAL FOR DEPRESSION Canada NewsWire Trial to investigate the effects of Filament's botanical psilocybin drug candidate and Cybin Therapeutics' protocols in treating major depressive disorde...

Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers Canada NewsWire Filament is one of a small number of Canadian companies to have Good Manufacturing Practices-compliant psilocybin drug candidates ente...

FILAMENT HEALTH AND CYBIN THERAPEUTICS ANNOUNCE LICENSING AGREEMENT Canada NewsWire Filament will license PEX010, its proprietary botanical psilocybin drug candidate, to Cybin Therapeutics for use in two upcoming Phase II clinical trials awaiting Health Canada approval...

Vancouver, British Columbia, January 4, 2022 – Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that Health Canada has approved a phase 2 clini...

FILAMENT HEALTH RECOGNIZES THE RESTORATION OF ACCESS TO RESTRICTED DRUGS VIA THE HEALTH CANADA SPECIAL ACCESS PROGRAM Canada NewsWire VANCOUVER, BC , Jan. 5, 2022 /CNW/ - Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7...